Improving Population Pharmacokinetic Modelling with Artificial Patients using Generative Artificial Intelligence.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Verena Schöning, Felix Hammann
{"title":"Improving Population Pharmacokinetic Modelling with Artificial Patients using Generative Artificial Intelligence.","authors":"Verena Schöning, Felix Hammann","doi":"10.1002/prp2.70241","DOIUrl":null,"url":null,"abstract":"<p><p>In population pharmacokinetics (PopPK), non-linear mixed effects (NLME) models are used to simultaneously describe a drug's pharmacokinetics (PK) and dynamics (PD) in a patient population using systems of ordinary differential equations. In this field, machine learning is mainly used for data preparation, hypothesis generation, predictive modeling, and model validation. Some approaches to integrate artificially generated information have already been explored, but real-world application is still limited. We therefore conducted a proof-of-concept study to analyze the ability of generative artificial intelligence (AI) to create artificial patient profiles to augment PopPK data sets and assess their influence on parameter estimates. We defined the pharmacokinetic parameters of a hypothetical drug and simulated the concentration curves of 20 patients. We then trained Wasserstein Generative Adversarial Networks (WGANs) with gradient penalty (GP) to generate artificial patients. The data distribution of original and artificial patients was statistically indistinguishable as shown by the Maximum Mean Discrepancy test. Therefore, the WGAN-GP is neither overfitted, that is producing only single instances of artificial patients, nor underfitted, that is producing unrealistic artificial patients. We then combined different shares of original and artificial patients in separate data sets to build and compare PopPK model estimates. Addition of artificial patients led to narrower confidence intervals, indicating more robust parameter estimates, and accentuated the allometric effect of weight on the volume of distribution. In conclusion, we provide a proof-of-concept that generative AI can be used to augment pharmacokinetic data sets, with preliminary evidence suggesting improved parameter estimation.</p>","PeriodicalId":19948,"journal":{"name":"Pharmacology Research & Perspectives","volume":"14 2","pages":"e70241"},"PeriodicalIF":2.6000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052321/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Research & Perspectives","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/prp2.70241","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In population pharmacokinetics (PopPK), non-linear mixed effects (NLME) models are used to simultaneously describe a drug's pharmacokinetics (PK) and dynamics (PD) in a patient population using systems of ordinary differential equations. In this field, machine learning is mainly used for data preparation, hypothesis generation, predictive modeling, and model validation. Some approaches to integrate artificially generated information have already been explored, but real-world application is still limited. We therefore conducted a proof-of-concept study to analyze the ability of generative artificial intelligence (AI) to create artificial patient profiles to augment PopPK data sets and assess their influence on parameter estimates. We defined the pharmacokinetic parameters of a hypothetical drug and simulated the concentration curves of 20 patients. We then trained Wasserstein Generative Adversarial Networks (WGANs) with gradient penalty (GP) to generate artificial patients. The data distribution of original and artificial patients was statistically indistinguishable as shown by the Maximum Mean Discrepancy test. Therefore, the WGAN-GP is neither overfitted, that is producing only single instances of artificial patients, nor underfitted, that is producing unrealistic artificial patients. We then combined different shares of original and artificial patients in separate data sets to build and compare PopPK model estimates. Addition of artificial patients led to narrower confidence intervals, indicating more robust parameter estimates, and accentuated the allometric effect of weight on the volume of distribution. In conclusion, we provide a proof-of-concept that generative AI can be used to augment pharmacokinetic data sets, with preliminary evidence suggesting improved parameter estimation.

利用生成式人工智能改进人工患者群体药代动力学建模。
在群体药代动力学(PopPK)中,非线性混合效应(NLME)模型使用常微分方程系统同时描述药物在患者群体中的药代动力学(PK)和动力学(PD)。在该领域,机器学习主要用于数据准备、假设生成、预测建模和模型验证。一些集成人工生成信息的方法已经被探索过,但实际应用仍然有限。因此,我们进行了一项概念验证研究,以分析生成式人工智能(AI)创建人工患者资料以增强PopPK数据集的能力,并评估其对参数估计的影响。我们定义了一种假设药物的药代动力学参数,并模拟了20例患者的浓度曲线。然后,我们训练带有梯度惩罚(GP)的Wasserstein生成对抗网络(wgan)来生成人工患者。通过最大平均差异检验,原始患者和人工患者的数据分布在统计学上无法区分。因此,WGAN-GP既不是过拟合(即只产生单个人工患者),也不是欠拟合(即产生不现实的人工患者)。然后,我们将原始患者和人工患者在不同数据集中的不同份额结合起来,建立并比较PopPK模型的估计。人工患者的加入导致置信区间更窄,表明参数估计更稳健,并强调了体重对分布体积的异速效应。总之,我们提供了一个概念验证,即生成式人工智能可以用来增强药代动力学数据集,初步证据表明参数估计得到了改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
5.30
自引率
3.80%
发文量
120
审稿时长
20 weeks
期刊介绍: PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书